Why Use AUMsilence Oligos for RNA Silencing?

AUMsilence ASOs vs. siRNAs
The basics
Not Required Transfection Reagents Required
AUMsilence oligo technology allows very high specificity for the target RNA Specificity siRNA grade specificity
None RISC associated Off target effects Yes
Easy and convenient single step process Transition from basic cell lines to primary cells to animal models Require extensive optimization and use of delivery reagents
Ease of use in different model systems
Easy to use. No transfection reagents required. Mix AUMsilence oligos with the cells Basic Cell lines Need transfection reagents. Transfection reagent based optimization required
Easy to use. No transfection reagents required. Mix AUMsilence ASO oligos with the cells Primary cells and difficult to transfect cells Need transfection reagents that kills the sensitive cells and sometimes alter the biology
Can work in fish models (example zebrafish) Fish models Not recommended for fish models
Key Attributes
Non-toxic Toxicity Can be toxic
Resistant to degradation by serum and cellular nucleases Stability Moderate stability
Minimal resources needed and easy to optimize Resources and time saving Require additional reagents and machines. Time consuming optimization
Up to 80% more cost effective in terms of time and money. Cost saving Expensive to use

AUMsilence ASO Technology

Publications on AUMsilence oligos

Journal of Autoimmunity, 2024

Gao et. al. Silencing of aryl hydrocarbon receptor repressor restrains Th17 cell immunity in autoimmune hepatitis

View Publication
Nature Communications, 2024

Mazzeo et. al. ANKRD1 is a mesenchymal-specific driver of cancer-associated fibroblast activation bridging androgen receptor loss to AP-1 activation

View Publication
Science, 2023

Zhang et. al. TRIM11 protects against tauopathies and is down-regulated in Alzheimer's disease

View Publication
Circulation, 2023

Zhang et. al. INKILN is a Novel Long Noncoding RNA Promoting Vascular Smooth Muscle Inflammation via Scaffolding MKL1 and USP10

View Publication
Nature Genetics, 2022

Marasca et. al. LINE1 are spliced in non-canonical transcript variants to regulate T cell quiescence and exhaustion

View Publication
Science Translational Medicine, 2022

Valle et. al. LINE-1 RNA causes heterochromatin erosion and is a target for amelioration of senescent phenotypes in progeroid syndromes

View Publication

Award Winning Technology

Researchers using AUM BioTech's RNA silencing products and services have received several NIH grants. We are proud to serve the global scientific community and help them advance biomedical research.

Protocols

Much more convenient than siRNA, shRNA or CRISPR

in vitro

No Transfection Reagents Needed (Self-Delivery Or Gymnosis)

We take pride in having the simplest protocol for RNA silencing studies. AUMsilence oligos can work with any cell type without causing toxicity. AUMsilence oligos can work with easy to transfect, hard to transfect (like primary cells, b-cells, t-cells, neurons etc.) and highly sensitive patient samples.

More..

in vivo

No Delivery Vehicle, Formulations Or Conjugates Needed

It is recommended to test a few doses of AUMsilence oligos. Recommended dose is between 3 – 30 mg/kg in mice. Administration routes: Depending upon your experimental purpose you may choose from Subcutaneous, Intrathecal, Oral or Intestinal.

More..

About us

AUM BioTech is a Philadelphia based biotechnology company with a revolutionary nucleic acids platform in the gene silencing and regulation space. AUM’s AUMsilence ASO RNA silencing and regulation technology can be used to very efficiently target a variety of RNA modalities like – mRNA, microRNA and long non-coding RNA. AUMsilence ASO technology can be used for discovery, translational and potentially for therapeutic development. Considering the versatility of our next generation RNA silencing and regulation platform AUM is now making the AUMsilence ASO technology available to biomedical researchers across the globe.